Sentence examples for cost effectiveness difference from inspiring English sources

Similarly we did not include studies that reported the cost-difference (or cost effectiveness difference) between alternative drug regimens whose efficacy was being compared in randomized controlled trials.

In patients aged >25 years, cost-effectiveness differences between strategies were minimal.

It would be interesting to examine CHW cost-effectiveness on the different components of RMNCH separately (for example, antenatal care and deliveries separately) and analyse cost and cost-effectiveness differences between these activities.

We hypothesized that selective excavation has greater cost-effectiveness-advantages over alternative treatments in patients with high compared with low risk, and additionally assessed the absolute and relative magnitude of the described cost-effectiveness differences between strategies and populations.

Apart from the cost – effectiveness, the difference in the general health status will be evaluated.

19 24 25 26 Results from this process of country contextualisation have shown a high degree of agreement with regional rankings of cost effectiveness, but differences in the absolute cost or specific effect of certain interventions (for example, because of locally applicable drug price tariffs in Nigeria or rates of heavy alcohol use in Thailand that were higher than the regional average).

Based on this study, IngMebs can result in effectiveness (QALY) gains at acceptable costs in their indication, significant cost and effectiveness differences can exist between the treatments, and treating AK in the PC setting (where feasible) can result in cost savings.

From the distributions of cost and effectiveness differences the probability that one setting is cost-effective compared to another is calculated depending on a range of values for the ceiling ratio λ and presented in the form of a cost-effectiveness acceptability curve [ 21, 22].

38 Bootstrap methods will be used to estimate the joint distribution of cost and effectiveness differences, and the proportion of replicates with ICERs less than commonly accepted benchmarks applicable to Australia will be presented.

The primary objective of the economic evaluation is to identify the within study incremental cost effectiveness ratios; the difference in costs between rituximab and placebo divided by the difference in benefits between rituximab and placebo.

To handle this aspect of reporting for such a wide range of interventions, we classified interventions according to their degree of cost effectiveness (not cost effective, cost effective, or very cost effective) in order to ascertain order of magnitude differences in cost effectiveness.